Transcenta Announced Presentation of Preclinical Data of TST005 at 2021 AACR Virtual Annual Meeting
- Wall Street ends volatile week sharply higher
- Disney (DIS) Dips As Streaming Business Shows Signs of Slowing Down, Analysts 'Very Bullish' on LT Opportunity
- Airbnb (ABNB) Bookings Up 52% to Help Sales Beat, Seen as a 'Blow Out Quarter' as More Upside is Left
- DoorDash (DASH) Reports Bigger Loss and a Sales Beat, Shares Soars on Strong Guidance and Two Upgrades to 'Buy'
- Coinbase (COIN) To Add Dogecoin Trading in the Next Few Weeks
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
SUZHOU, China, April 15, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, presented preclinical data of TST005, a bi-functional anti-PD-L1 and TGF-β trap fusion protein, in a poster during the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting, being held from April 10th to 15th and May 17th to 21st.
Title:The preclinical characterization of TST005, a bi-functional anti-PD-L1 and TGF-β trap fusion protein
Abstract Number: 972Poster Number: 917
Session Category:Antibody Technologies
Session Title:Experimental and Molecular Therapeutics
Poster launch time: April 10th, 2021, 8:30 a.m.ET, U.S. time
About TST005TST005, is a bi-functional anti-PD-L1 and TGF-β trap fusion protein designed to simultaneously target two immuno-suppressive pathways, transforming growth factor β-(TGF-β) and programmed cell death ligand-1 (PD-L1), that are commonly used by cancer cells to evade the immune system. TST005 consists of a high affinity PD-L1 antibody fused with an engineered TGF-β Receptor Type II protein in its C-terminal. TST005 lacks FcR binding and has reduced risk of FcR mediated killing of PD-L1 expressing effector T cells. TST005's PD-L1 high binding activity and enhanced TGF-β trap stability enables the targeted delivery of TGF-β trap into PD-L1 expressing tumors, thereby minimizing off-target toxicities of systemic inhibition of TGF-β signaling. TST005 displayed potent activity in vitro in reversing TGF-β induced T-cell suppression. In multiple syngeneic tumor models, TST005 induced significant increase of CD8 T-cell infiltration into PD-L1 expressing tumors and displayed dose-dependent tumor growth inhibition. TST005 is well tolerated in non-human primates and displayed a linear PK profile. TST005 is a potential novel bi-functional immunotherapy candidate with improved therapeutic window.
About Transcenta Holding Limited Transcenta is a clinical stage global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development and manufacturing. With Headquarters and Discovery and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in Beijing, Shanghai and Guangzhou in China and in Princeton, US, and External Partnering Center in Boston, US, Transcenta has established global footprint. Transcenta is developing a panel of nine antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders. Upon the latest financing, the company has raised over $342 million from globally prominent investors. For more information, please visit www.transcenta.com.
SOURCE Transcenta Holding Limited
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- After 59 Years, the Families of Flying Tiger Line Flight 739 Receive Closure
- Lorain County Community College Honors Graduating Class with "Doors of Opportunity"
- ISMRM-SMRT Annual Meeting Features Distinguished Speaker Program
Create E-mail Alert Related CategoriesPRNewswire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!